Search research articles
Contact Us
Filters
Showing results (651-660 of 993) with videos related to
Page
of 100
Sort By:
The Prostate
|
June 23, 2026
Years of Life Lost From Metastatic Prostate Cancer According to Treatment Era and Race/Ethnicity
Leonardo Quarta, Michele Petix, Maximilian Filzmayer, et al.
Annals of Surgical Oncology
|
December 3, 2024
Perioperative Complications and In-Hospital Mortality in Radical Nephroureterectomy Patients with Heart Valve Replacement
Francesco Di Bello, Natali Rodriguez Peñaranda, Carolin Siech, et al.
The Prostate
|
October 18, 2021
Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients
Benedikt Hoeh, Christoph Würnschimmel, Rocco S Flammia, et al.
International Urology and Nephrology
|
November 16, 2021
Cancer-specific mortality after radical prostatectomy vs external beam radiotherapy in high-risk Hispanic/Latino prostate cancer patients
Benedikt Hoeh, Jan L Hohenhorst, Rocco Flammia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 30, 2005
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer
Matthew R Smith, Fairooz Kabbinavar, Fred Saad, et al.
Pathology Oncology Research : POR
|
April 7, 2018
A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores
Sami-Ramzi Leyh-Bannurah, Dominique Trudel, Mathieu Latour, et al.
Urologic Oncology
|
February 19, 2013
Multifocality rather than tumor location is a prognostic factor in upper tract urothelial carcinoma
Andrew K Williams, Wassim Kassouf, Joseph Chin, et al.
European Urology
|
March 19, 2017
Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302
Matthew R Smith, Fred Saad, Dana E Rathkopf, et al.
The Lancet. Oncology
|
February 14, 2022
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial
Antoine Thiery-Vuillemin, Johann de Bono, Maha Hussain, et al.
The Prostate
|
April 11, 2022
Contemporary seminal vesicle invasion rates in NCCN high-risk prostate cancer patients
Rocco S Flammia, Benedikt Hoeh, Gabriele Sorce, et al.
Page
of 100
Search research articles
Search
Showing results (651-660 of 993) with videos related to
Sort By:
Page
of 100
The Prostate
|
June 23, 2026
Years of Life Lost From Metastatic Prostate Cancer According to Treatment Era and Race/Ethnicity
Leonardo Quarta, Michele Petix, Maximilian Filzmayer, et al.
Annals of Surgical Oncology
|
December 3, 2024
Perioperative Complications and In-Hospital Mortality in Radical Nephroureterectomy Patients with Heart Valve Replacement
Francesco Di Bello, Natali Rodriguez Peñaranda, Carolin Siech, et al.
The Prostate
|
October 18, 2021
Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients
Benedikt Hoeh, Christoph Würnschimmel, Rocco S Flammia, et al.
International Urology and Nephrology
|
November 16, 2021
Cancer-specific mortality after radical prostatectomy vs external beam radiotherapy in high-risk Hispanic/Latino prostate cancer patients
Benedikt Hoeh, Jan L Hohenhorst, Rocco Flammia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 30, 2005
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer
Matthew R Smith, Fairooz Kabbinavar, Fred Saad, et al.
Pathology Oncology Research : POR
|
April 7, 2018
A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores
Sami-Ramzi Leyh-Bannurah, Dominique Trudel, Mathieu Latour, et al.
Urologic Oncology
|
February 19, 2013
Multifocality rather than tumor location is a prognostic factor in upper tract urothelial carcinoma
Andrew K Williams, Wassim Kassouf, Joseph Chin, et al.
European Urology
|
March 19, 2017
Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302
Matthew R Smith, Fred Saad, Dana E Rathkopf, et al.
The Lancet. Oncology
|
February 14, 2022
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial
Antoine Thiery-Vuillemin, Johann de Bono, Maha Hussain, et al.
The Prostate
|
April 11, 2022
Contemporary seminal vesicle invasion rates in NCCN high-risk prostate cancer patients
Rocco S Flammia, Benedikt Hoeh, Gabriele Sorce, et al.
Page
of 100